Follicular lymphoma is the second most common sub-type of non-Hodgkin
lymphoma (NHL), which accounts for more than 20% of all NHL cases.
Follicular lymphoma is highly indolent. The most common sub-type of
NHL is diffuse large B-cell lymphoma (DLBCL). Follicular lymphoma is
referred to as cancer of the lymphatic system. The lymphatic system
is a part of the body’s immune system. It comprises the spleen, the
thymus, the lymph nodes, the tonsils, the lymph tissue, and the bone
marrow. Cancerous growth of follicular lymphomas is slower than other
sub-types of NHL. Follicular lymphoma primarily results in abnormal
formation of B-lymphocytes in the lymph nodes. B-lymphocytes is a
type of white blood cells and a key constituent of the human immune
system. Major symptoms of follicular lymphoma include shortness of
breath; fatigue; night sweats; weight loss; and enlargement of the
lymph nodes in the neck, the groin, and the abdomen. According to the
National Cancer Institute, NIH, the U.S., more than 72,000 people in
the U.S. alone would be diagnosed with some form of NHL and more than
20,000 patients with NHL would die by the end of 2017. The follicular
lymphoma disease can be diagnosed by using biopsy, radiology, blood
tests, etc. Follicular lymphoma can be treated by using radiation
therapy, chemotherapy, targeted therapy, and stem cell
transplantation.
Report Overview @
https://www.transparencymarketresearch.com/follicular-lymphoma-treatment-market.html
Some of the key factors that would drive the global follicular
lymphoma treatment market in the near future are rising prevalence of
follicular lymphoma, family history of the disease, and increasing
incidence of blood disorders worldwide. In addition, increasing
research and development activities for innovation of newer drugs and
treatment methods and technological advancements in disease diagnosis
would further fuel the follicular lymphoma market in the near future.
However, strict regulatory requirements for drug approval, high
treatment cost, and adverse effects associated with different
treatment methods may restrain the market during the forecast period.
Furthermore, a large number of promising pipeline drugs and newer
therapies such as monoclonal antibodies along with government
initiatives for cancer management are anticipated to boost the market
during the forecast period.
The follicular lymphoma treatment market can be segmented based on
treatment type, route of administration, end-user/distribution
channel, and geography. Based on treatment type, the market can be
segmented into chemotherapy, targeted therapy, radiotherapy,
monoclonal antibodies, and stem cell transplantation. The
chemotherapy segment can be sub-segmented into alkylating agents,
nucleoside analogues, anthracycline derivatives, and others. Based on
route of administration, the follicular lymphoma treatment market can
be segmented into oral, parenteral, and others. Based on
end-user/distribution channel, the market can be divided into
hospitals, retail pharmacies, oncology centers, and academic &
research institutes.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35840
Geographically, the global follicular lymphoma treatment market can
be segmented into five regions viz. North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. The North
America follicular lymphoma treatment market is poised to witness
significant growth during the forecast period, as a few recent
surveys have estimated high growth in the prevalence of the disease
in the region, especially in the U.S., in the near future. Current
trends observed in pipeline drugs for the treatment of follicular
lymphoma also indicate high growth opportunities for the North
America follicular lymphoma treatment market. The market in Europe is
also anticipated to expand significantly during the forecast period,
due to well-established health care infrastructure and increase in
the prevalence of follicular lymphoma in the region. Other regions
such as Asia Pacific, Latin America, and Middle East & Africa
present lucrative opportunities for growth of the follicular lymphoma
treatment market, owing to large patient pool in these regions,
growing awareness about the disease, and availability of options for
its management.
Some of the key players operating in the global follicular lymphoma
treatment market are AbbVie, Inc., Bayer AG, Bristol Myers Squibb and
Company, Epizyme Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline
plc, Johnson and Johnson Services, Inc., Merck & Co. Inc., and
Novartis AG.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=35840<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment